CP-45,899 {3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide, [2S-(2a,5a)]} is an irreversible inhibitor of several bacterial penicillinases and cephalosporinases. In the presence of low concentrations of CP-45,899, ampicillin and other f,-lactams readily inhibit the growth of a variety of resistant bacteria that contain ,-lactamases. 899 In vitro susceptibility studies were performed in brain heart infusion broth as the basal medium. The broth was enriched with 5% (vol/vol) sheep blood for studies with Streptococcus pyogenes and 5% Fildes plus 2% IsoVitaleX for Haemophilus influenzae. Tests with Neisseria gonorrhoeae were performed on gonococcus agar base (BBL) supplemented with hemoglobin and IsoVitaleX. Studies with Bacteroides fragilis were carried out in prereduced brain heart infusion as described in the Anaerobe Laboratory Manual (3); incubation was in an 80% N2-10% C02-10% H2 gas mixture either in an anaerobic chamber or in GasPak jars equipped with gas-exchange capability.
A primary objective of penicillin and cephalosporin research over the past two decades has been to improve their antibacterial spectrum by chemically modifying their structures to prevent degradation by the f-lactamases of resistant bacteria. An alternate approach to this problem is to design an agent whose sole purpose is to irreversibly inhibit these ft-lactamase enzymes.
Such an agent need not possess antibacterial activity of its own, but would be used in conjunction with existing ,B-lactam antibiotics to afford activity against otherwise resistant bacteria. One such agent, the fermentation product clavulanic acid, has recently been described by Brown et al. (2) . We describe here a new semisynthetic /8-lactamase inhibitor, CP-45,899, which has features in common with clavulanic acid but which also has some potential practical advantages.
MATERIALS AND METHODS
Materials. CP-45,899 is a water-soluble, white crystalline solid, which was designed and synthesized by one of us (W.E.B.). Antibiotics, ampicillin, penicillin G, and carbenicillin, were obtained from Pfizer Inc. Cefazolin and cephaloridine were purchased from local suppliers. Clavulanic acid was a gift from Beecham Laboratories. The bacteria used were primarily clinical isolates that have been maintained in our laboratories for some years.
In vitro susceptibility studies were performed in brain heart infusion broth as the basal medium. The broth was enriched with 5% (vol/vol) sheep blood for studies with Streptococcus pyogenes and 5% Fildes plus 2% IsoVitaleX for Haemophilus influenzae. Tests with Neisseria gonorrhoeae were performed on gonococcus agar base (BBL) supplemented with hemoglobin and IsoVitaleX. Studies with Bacteroides fragilis were carried out in prereduced brain heart infusion as described in the Anaerobe Laboratory Manual (3); incubation was in an 80% N2-10% C02-10% H2 gas mixture either in an anaerobic chamber or in GasPak jars equipped with gas-exchange capability.
Methods. Minimal inhibitory concentrations (MICs) of antibiotics in combination with CP-45,899 were determined using a 7-by-7-concentration grid protocol in broth culture, as described by Sabath (8) , with an inoculum of-i0 colony-forming units per ml.
Testing for synergy against B. fragilis was performed by an agar dilution method similar to the broth dilution method.
p8-Lactamase studies. The hydrolysis of ampicillin and penicillin G was determined by the microiodometric method of Novick (5) . Cephaloridine hydrolysis was measured by following the decrease in ultraviolet absorbance at 255 nm (6) . Conditions for both assays were identical: 0.5 M potassium phosphate, pH 6.5, and 37°C. Reactions were initiated by the addition of the cell-free ,B-lactamase, except in the case of preincubation experiments in which the inhibitor and enzyme were incubated together in the assay mixture for 10 min before initiation of the reaction by addition of substrate. With the cell-free extracts of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, the substrate was ampicillin at 33 i.M (13 ,ug/ml). The Table 2 , only E. coli and E. cloacae remained relatively unsusceptible to CP-45,899-ampicillin combinations (9) .
CP-45,899 also expanded the spectrum of /3-lactam antibiotics other than ampicillin. As seen in Table 3 Table 5 indicate that clavulanic coli, the difference was quite significant. Since acid-ampicillin combinations had somewhat CP-45,899 appeared equally active as an inhibi- 
